ABSTRACT
We evaluated the diagnostic performance of 4 commercially NAAT for detecting SARS-CoV-2 RNA, Influenza type A/B virus and RSV. Included tests were the Allplex™ SARS-CoV-2 fast PCR Assay (RNA extraction-free), Allplex™ RV Master Assay, Allplex™ SARS-CoV-2 fast MDx Assay (LAMP) and Aptima™ SARS-CoV-2/Flu Assay (RT-TMA). The assays' performance characteristics were determined using nasopharyngeal swabs from 270 patients with suspected SARS-CoV-2 infection. A total of 215 SARS-CoV-2 positive, 55 negative nasopharyngeal swabs and 19 bacteria strains were included. The sensitivities and specificities for detecting SARS-CoV-2, Influenza type A virus and RSV ranged between 81.8% and 100% with extremely good agreements (κ ≥ 86.8 %). The Aptima™ SARS-CoV-2/Flu Assay introduced a new result parameter, that is, TTime. Here, we showed that TTime may be used as a surrogate for Ct-value. We concluded that all assays assessed in this study can be used for routine detection of SARS-CoV-2, Influenza type A virus and RSV.
Subject(s)
COVID-19 , Herpesvirus 1, Cercopithecine , Influenza A virus , Influenza, Human , Humans , SARS-CoV-2/genetics , COVID-19/diagnosis , Herpesvirus 1, Cercopithecine/genetics , Influenza, Human/diagnosis , RNA, Viral/genetics , Influenza A virus/genetics , Sensitivity and Specificity , Nasopharynx , COVID-19 TestingABSTRACT
The aim of this paper is to describe the prevalence of Mycoplasma genitalium and Trichomonas vaginalis in patients who visited general practitioners in the Netherlands. Additionally, we describe the prevalence of M. genitalium resistance to azithromycin and moxifloxacin. We used data from 7,411 consecutive female patients who were screened for Chlamydia trachomatis, Neisseria gonorrhoeae, M. genitalium, and T. vaginalis and data from 5,732 consecutive male patients screened for C. trachomatis, N. gonorrhoeae, and M. genitalium. The prevalence of M. genitalium and T. vaginalis in female patients was 6.7% (95% CI: 6.2 to 7.4) and 1.9% (95%CI: 1.6 to 2.2%), respectively. M. genitalium prevalence in male patients was 3.7% (3.3 to 4.3). M. genitalium co-occurred with C. trachomatis in 1.4% (0.3 to 0.6%) of female and in 0.7% (0.5 to 0.9) of male patients. Macrolide resistance gene mutations and fluoroquinolone resistance gene mutations were detected in 73.8% and 9.9%, respectively. We concluded that M.genitalium is relatively infrequently found in a large general practitioner population in the Netherlands. It can co-occur with C. trachomatis, and is often resistant to azithromycin. Therefore, when treating sexually transmitted infections, these prevalence and resistance data should be taken into account.
Subject(s)
Chlamydia trachomatis , Drug Resistance, Bacterial , Mycoplasma Infections , Mycoplasma genitalium , Sexually Transmitted Diseases , Trichomonas Vaginitis , Trichomonas vaginalis , Female , Humans , Male , Anti-Bacterial Agents/therapeutic use , Azithromycin/therapeutic use , Chlamydia trachomatis/drug effects , Chlamydia trachomatis/genetics , Drug Resistance, Bacterial/genetics , Macrolides , Mycoplasma genitalium/drug effects , Mycoplasma genitalium/genetics , Mycoplasma Infections/diagnosis , Mycoplasma Infections/drug therapy , Mycoplasma Infections/epidemiology , Neisseria gonorrhoeae/genetics , Netherlands/epidemiology , Prevalence , Primary Health Care , Sexually Transmitted Diseases/epidemiology , Trichomonas vaginalis/genetics , Trichomonas Vaginitis/diagnosis , Trichomonas Vaginitis/drug therapy , Trichomonas Vaginitis/epidemiology , CoinfectionABSTRACT
OBJECTIVES: We assessed the performance of the Seegene Novaplex™ Dermatophyte Assay for diagnosis of dermatophytosis. METHODS: Sixty-one clinical samples from skin, nail, hair and culture were selected based on RT-PCR according to Wisselink et al. Of these samples, 26 samples were negative and 35 samples were positive with 39 dermatophytes strains. Emerging fungal strains harbouring terbinafine resistance (i.e. T. indotineae and T. mentagrophytes) were included. RESULTS: The specificities of the Novaplex™ Dermatophyte Assay ranged between 94.3% and 97.9%. The sensitivities for the detection of T. rubrum complex, T. mentagrophytes/T. interdigitale species complex and C. albicans were 94.1% (95% CI: 71.3-99.9), 78.6% (95% CI: 49.2-95.3) and 100% (95% CI: 69.2-100), respectively, with Cohen's kappa of at least 72.9%. CONCLUSIONS: The Seegene Novaplex™ Dermatophyte Assay can be used for reliable screening of dermatophytes, including emerging strains in a routine laboratory setting.
